II-VI, Inc. (IIVI) Tops Q4 EPS by 16c

II-VI, Inc. (NASDAQ: IIVI) reported Q4 EPS of $0.40, $0.16 better than the analyst estimate of $0.24. Revenue for the quarter came in at $241.4 million versus the consensus estimate of $214.13 million.

The Company’s Board of Directors has appointed Dr. Vincent D. Mattera, Jr. as President and Chief Executive Officer effective September 1, 2016 following the retirement of current CEO Francis J. Kramer. Dr. Mattera has served as the President since 2014.

Dr. Mattera was a member of the II-VI Board of Directors from 2000 to 2002 before joining the Company in 2004 as a Vice President. Prior to that, he held several leading positions over 20 years at AT&T Bell Laboratories, Lucent Technologies Microelectronics Division, and Agere Systems. Dr. Mattera was re-elected to the Board in 2014.

Francis J. Kramer has served as the CEO since 2007 and will continue as the Chairman of the Board of Directors. Mr. Kramer joined the Company in 1983. In his 33 year tenure, Mr. Kramer led the Company’s growth to become the international market leader it is today. He successfully completed 20 acquisitions in 20 years, drove the Company’s manufacturing and sales footprint, diversified the Company’s product portfolio and established the culture that focuses on the consistent delivery of strategic, profitable growth worldwide.

Francis J. Kramer, Chairman and Chief Executive Officer, said, “FY16 was a solid and exciting year for II-VI. All segments showed progress in the market, contributed to improvements in the Company’s overall margins, and will enter fiscal year 2017 with favorable momentum. Much of this success is due to the strategic moves we’ve made during Chuck Mattera’s tenure with II-VI. I’m very happy to congratulate Chuck on this well-deserved appointment. He will make a great CEO for II-VI, the third in our 45 year history, with his extensive market and technology development experience, his knowledge of our worldwide operations and customers, and his dedication to II-VI. He has a very good and extensive team throughout the Company to support him and we all look forward to his success.”

“Regarding our investments, the additional R&D and capital platform investments we are planning to make over the next four to five quarters are intended to position us to capture a meaningful market share in end markets with expected growth in the billions of dollars over the next several years. Many of these markets are still in the early stages of growth. While there are risks with respect to timing and speed of adoption, the platforms we are targeting build on many technologies in which II-VI has a strong competitive advantage. We expect the returns on our investment to be accretive within the next two years.”

GUIDANCE:

II-VI, Inc. sees Q1 2017 EPS of $0.22-$0.27, versus the consensus of $0.26. II-VI, Inc. sees Q1 2017 revenue of $210-225 million, versus the consensus of $212.9 million.

For earnings history and earnings-related data on II-VI, Inc. (IIVI) click here.

You May Also Be Interested In

• Biogen (BIIB) tops earnings expectations but revenue falls short
• PROG Holdings Inc (PRG) Tops Q1 EPS by 9c
• Bok Financial Corp (BOKF) Misses Q1 EPS by 27c